Principal Investigator: Karen Salzman
Keywords: Brain MRI , Brain Tumor Department: Radiology Clinical
IRB Number: 00058762 Co Investigator: Howard Colman
Specialty: Radiology, Radiology
Sub Specialties: Neuroradiology, Magnetic Resonance Imaging – MRI
Recruitment Status: Recruiting

Contact Information

Collin Arsenault
collin.arsenault@hsc.utah.edu
(801) 587-8638

Simple Summary

1) To evaluate the utility of both pre and post treatment spectroscopy and perfusion imaging in both primary and metastatic brain neoplasms to predict or demonstrate response or progression.2) To determine characteristic imaging/metabolic features that would discern recurrent and/or residual tumor from treatment response.3) To look for associations between the tumor characteristic (parameters measured in Objective 1) with the duration of progression-free and overall patient survival.

Inclusion Criteria

Study patients:  Adult patients (18 years or older) with primary brain neoplasms or brain metastasis. We expect that up to 100 total people may be enrolled in this study.

The patient population will comprise patients suspected to have or confirmed to have a brain glial neoplasm or metastases by MRI who are at least 18 years of age.

Exclusion Criteria

Exclusion criteria:  Patients will be excluded if they are unable to sign the consent form. Exclusions due to use of MR imaging include having a cardiac pacemaker, certain types of cerebral aneurysm clips, ferromagnetic foreign bodies, claustrophobia requiring conscious sedation or general anesthesia, and pregnancy.

Participant Reimbursement

None